Skip to main content

Table 3 Response to treatment in relation to biomarkers expression considered as per clinical practicea

From: Androgen receptor in advanced breast cancer: is it useful to predict the efficacy of anti-estrogen therapy?

  No. CR or PR or SD PD p
No. (%) No. (%)
ER status
  < 1% 1 0 1 (100)  
  ≥ 1% 72 64 (88.9) 8 (11.1) 0.123
PgR status
  < 1% 15 11 (73.3) 4 (26.7)  
  ≥ 1% 58 53 (91.4) 5 (8.6) 0.079
Ki67 status
  < 20% 46 44 (95.7) 2 (4.3)  
  ≥ 20% 26 19 (73.1) 7 (26.9) 0.009
HER2 status
 Negative 64 57 (89.1) 7 (10.9)  
 Positive 9 7 (77.8) 2 (22.2) 0.306
AR status
  < 1% 12 10 (83.3) 2 (16.7)  
  ≥ 1% 61 54 (88.5) 7 (11.5) 0.619
  < 10% 19 15 (79.0) 4 (21.0)  
  ≥ 10% 54 49 (90.7) 5 (9.3) 0.182
AR/ER ratio
  < 0.90 (best cutoff) 38 31 (81.6) 7 (18.4)  
  ≥ 0.90 (best cutoff) 35 33 (94.3) 2 (5.7) 0.101
AR/PgR ratio
  < 0.96 (best cutoff) 27 23 (85.2) 4 (14.8)  
  ≥ 0.96 (best cutoff) 46 41 (89.1) 5 (10.9) 0.623
  1. Abbreviations: CR complete response, PR partial response, SD stable disease, PD progressive disease, ER estrogen receptor, PgR progesterone receptor, AR androgen receptor, HER2 human epidermal growth factor receptor 2
  2. abiomarker measured on metastatic sample when a metastatic biopsy was available, or on primary tumor when biopsy of metastasis had not been performed